SCHEMBL8835918

SCHEMBL8835918

c1csc(-c2cnc3[nH]c4ccccc4c3n2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 7/20 0.50
▸ RAB9A P51151 7/20 0.50
▸ KDM4E B2RXH2 6/20 0.50
▸ HPGD P15428 5/20 0.50
▸ ALDH1A1 P00352 5/20 0.50
▸ SMN1; SMN2 Q16637 4/20 0.50
▸ CASP1 P29466 4/20 0.50
▸ CASP7 P55210 4/20 0.50
▸ HSD17B10 Q99714 4/20 0.50
▸ MAPK10 P53779 3/20 0.50
▸ GAA P10253 3/20 0.50
▸ NOS1 P29475 1/20 0.48
▸ TDO2 P48775 1/20 0.46
▸ TP53 P04637 2/20 0.45
▸ POLB P06746 1/20 0.45
▸ ADORA3 P0DMS8 1/20 0.44
▸ MAPT P10636 4/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ LMNA P02545 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31232962 0.78 KDM4E (0.47) NPC1RAB9AKDM4EHPGDALDH1A1
SCHEMBL8836341 0.78 POLB (0.51) NPC1RAB9AKDM4EHPGDALDH1A1
SCHEMBL8835838 0.73 NPC1 (0.46) NPC1RAB9AALDH1A1SMN1; SMN2CASP1
SCHEMBL8835557 0.73 NOS1 (0.46) NPC1RAB9AKDM4EHPGDALDH1A1
SCHEMBL20730409 0.71 PDK2 (0.55) NPC1RAB9AKDM4EHPGDALDH1A1
SCHEMBL8836333 0.70 MAPK1 (0.51) NPC1RAB9AKDM4EHPGDALDH1A1
SCHEMBL29669831 0.69 ALDH1A1 (0.50) NPC1RAB9AKDM4EHPGDALDH1A1
SCHEMBL8836358 0.68 NR1I2 (0.53) CYP1A2CYP2C9
SCHEMBL31232967 0.68 TDO2 (0.60) NPC1RAB9AKDM4EHPGDALDH1A1
SCHEMBL708998 0.67 NPC1 (1.00) NPC1RAB9AKDM4EHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5606059-A USEFUL IN THE DIAGNOSIS AND TREATMENT OF ANXIETY, SLEEP AND SEIZURE DISORDERS, OVERDOSE WITH BENZODIAZEPINE TYPE DRUGS AND THE ENHANCEMENT OF ALERTNESS NEUROGEN CORPORATION (US) 1997-02-25 — — US claimed
US-5668283-A Certain aryl substituted pyrrolopyrazines; a new class of GABA brain receptor ligands NEUROGEN CORPORATION (US) 1997-09-16 — — US disclosed
US-5606059-A USEFUL IN THE DIAGNOSIS AND TREATMENT OF ANXIETY, SLEEP AND SEIZURE DISORDERS, OVERDOSE WITH BENZODIAZEPINE TYPE DRUGS AND THE ENHANCEMENT OF ALERTNESS NEUROGEN CORPORATION (US) 1997-02-25 — — US disclosed
WO-1994011374-A1 CERTAIN ARYL SUBSTITUTED PYRROLOPYRAZINES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS NEUROGEN CORPORATION (US) 1994-05-26 — — WO disclosed
US-5286860-A Certain aryl substituted pyrrolopyrazines; a new class of GABA brain receptor ligands NEUROGEN CORPORATION (US) 1994-02-15 — — US disclosed
Send feedback